Fig. 5From: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patientsRelationship between baseline levels CD4+CD26high and treatment response to nivolumab. Box plots showing the correlation between median (25th; 75th percentile) levels of CD26high cells, DCR (A), and BORR (B) of melanoma patients under treatment of nivolumab at 12 monthsBack to article page